This site is intended for health professionals only
Monday 19 February 2018
Share |

Latest News

New data demonstrates long-term skin clearance in patients treated with guselkumab

Monday 19th February 2018

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced new data that showed a vast majority of patients with moderate to severe plaque psoriasis receiving Tremfya® (guselkumab), who achieved at least a 90% improvement in the Psoriasis Area and Severity Index (PASI 90) at week 28, maintained a PASI 90 response with continuous treatment through week 72.1

Findings from the study also demonstrated that a vast majority of...

Mon, 19 Feb 2018
PANTS study shows that CT-P13 is an efficacious therapy option when investigating personalised approaches to anti-TNF therapy
Fri, 16 Feb 2018
Nusinersen demonstrated stabilisation or improvement from baseline in motor function in individuals with 5q spinal muscular atrophy where the natural history of the disease is a decline in motor function over time
Fri, 16 Feb 2018
NICE recommends NHS-wide prescribing of Ipsen’s cabozantinib for patients with medullary thyroid cancer
Fri, 16 Feb 2018
Study authors call for more research that could guide EU pollution regulations
Thu, 15 Feb 2018
Positive NICE recommendation ensures access to Eisai's lenvatinib for subset of patients with very limited options
Thu, 15 Feb 2018
Patient safety and clinical governance are major priorities for any NHS Trust, so ensuring both the accuracy and speed of a test result, and its confirmed match to the patient is essential
Thu, 15 Feb 2018
With the current situation, diagnosis of atrial fibrillation is a lengthy and expensive process, sometimes taking years